Sareum Holdings PLC
("Sareum" or "the Company")
Director/ PDMR Shareholding
Sareum announces that Susan Parker, wife of Dr Stephen Parker, Sareum's Chairman, purchased 609,756 of Ordinary Shares at a price of 0.82 pence per share yesterday. Following this transaction, Susan Parker now holds an interest of 1,284,028 Ordinary Shares in the company representing approximately 0.047% of the issued share capital of the Company. Dr. Parker and Susan Parker together now own a total of 1,745,977 Ordinary Shares, representing 0.064% of the Company's issued share capital.
For further information, please contact:
Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
WH Ireland Limited (Nominated Adviser) |
|
Chris Fielding / James Sinclair-Ford |
020 7220 1666 |
Hybridan LLP (Broker) |
|
Claire Noyce |
020 3764 2341 |
Citigate Dewe Rogerson (Media enquiries) |
|
Shabnam Bashir/ Mark Swallow/ David Dible |
020 7282 9571 |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 |
Details of the person discharging managerial responsibilities/person closely associated |
a) |
Name |
Susan Parker |
2 |
Reason for the notification |
a) |
Position/status |
PCA as wife of Chairman, Dr Stephen Parker, Sareum Holdings plc |
b) |
Initial notification/ Amendment |
Initial Notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Sareum Holdings plc |
b) |
LEI |
213800PKERN2DY8FFM72 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 0.025p each GB00B02RFS12 |
b) |
Nature of the transaction |
Purchase of shares |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
0.82p |
609,756 shares |
|
d) |
Aggregated information - Aggregated volume - Price |
609,756 0.82p |
e) |
Date of the transaction |
10th July 2018 |
f) |
Place of the transaction |
London Stock Exchange, AIM |
Notes for editors:
Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and undergoing Phase 2 clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in genetically defined patients both as a monotherapy and in combination with other oncology and immuno-oncology drugs.
Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.
The Company's drug discovery technology platform (SKIL(R) - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk
